Rajat Thawani, Assistant Professor at the Knight Cancer Institute at OHSU, shared on LinkedIn:
“Probably a path forward for accessing sunvozertinib for patients with EGFR exon 20 insertion mutations. Even with an FDA approval, sunvozertinib has been hard to acquire for patients.
EGFR exon 20 insertions have long been considered harder to target than the more common EGFR mutations, so having a therapy available is a meaningful step for a group of patients with more limited options.”
